Gilead Sciences, Inc. Gilead has retained exclusive rights in the Patents identified by a "Gilead" in the Third Party column to make, have made, use, import, export or sell compounds and other subject matter claimed within the scope of the patents which are [**]. In addition, Gilead has a non-exclusive, non-sublicensable, non-assignable license under such Patents to make and use CodeBlocker Compounds and Oligonucleotide Delivery Systems for internal research purposes, but not for any commercial purpose.
Appears in 2 contracts
Samples: Collaboration and License Agreement (Alnylam Pharmaceuticals Inc), Collaboration and License Agreement (Alnylam Pharmaceuticals Inc)
Gilead Sciences, Inc. Gilead has retained exclusive rights in the Patents identified by a "“Gilead" ” in the Third Party column to make, have made, use, import, export or sell compounds and other subject matter claimed within the scope of the patents which are [***]. In addition, Gilead has a non-exclusive, non-sublicensable, non-assignable license under such Patents to make and use CodeBlocker Compounds and Oligonucleotide Delivery Systems for internal research purposes, but not for any commercial purpose.
Appears in 1 contract
Gilead Sciences, Inc. Gilead has retained exclusive rights in the Patents identified by a "“Gilead" ” in the Third Party column to make, have made, use, import, export or sell compounds and other subject matter claimed within the scope of the patents which are [**]. In addition, Gilead has a non-exclusive, non-sublicensable, non-assignable license under such Patents to make and use CodeBlocker Compounds and Oligonucleotide Delivery Systems for internal research purposes, but not for any commercial purpose.
Appears in 1 contract
Samples: Strategic Collaboration and License Agreement (Alnylam Pharmaceuticals, Inc.)
